ASF1A and breast carcinoma: Next, we demonstrated USP52 deficiency rendered breast cancer cells hypersensitive to camptothecin (CPT) (Fig. 7d), a type of DNA damaging agent impairing replication fork progression, while cells stably expressing ASF1A overcome the effect induced by USP52 depletion (Fig. 7e).